Related Experiment Videos
[Clinical study of the month. The CHARM study]
1Université de Liège.
Revue Medicale De Liege
|December 18, 2003
Summary
Candesartan significantly reduced cardiovascular death and heart failure hospitalizations in patients with symptomatic heart failure (SHF). This study highlights candesartan
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Symptomatic heart failure (SHF) poses a significant clinical challenge.
- Optimizing treatment for SHF, particularly in diverse patient populations, remains a priority.
- The role of angiotensin receptor blockers like candesartan in SHF management requires further elucidation.
Purpose of the Study:
- To evaluate the efficacy of candesartan in reducing mortality and hospitalizations in patients with symptomatic heart failure.
- To assess candesartan's impact across different SHF patient profiles, including those intolerant to ACE inhibitors and those already on them.
- To investigate candesartan's effect on cardiovascular death, heart failure hospital admissions, and new-onset diabetes.
Main Methods:
- Parallel, randomized, double-blind, controlled clinical trials (CHARM program) involving three distinct SHF populations.
- Candesartan (titrated to 32 mg daily) was compared against placebo.
- Primary endpoint in CHARM-Overall was all-cause mortality; component trials focused on a composite of cardiovascular death and heart failure hospitalization.
Main Results:
- Candesartan showed a statistically significant reduction in all-cause mortality (adjusted HR: 0.90) in the overall program.
- A highly significant reduction in cardiovascular death and heart failure hospital admissions was observed (HR: 0.84).
- Candesartan reduced the incidence of new-onset diabetes and demonstrated benefits across subgroups, including those on beta-blockers. In CHARM-Preserved, admissions for heart failure were reduced.
Conclusions:
- Candesartan is effective in reducing cardiovascular death and heart failure hospitalizations in patients with symptomatic heart failure.
- The drug demonstrates benefits across various SHF patient groups, including those with preserved ejection fraction.
- Candesartan offers a valuable therapeutic option for managing symptomatic heart failure, potentially reducing comorbidities like new-onset diabetes.